Impact of everolimus on liver regeneration after partial liver transplantation

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K17581
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Kyoto University
• Principal Investigator: Sonoda Mari 京都大学, 医学研究科, 客員研究員 (40534235)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: エベロリムス / 生体部分肝移植 / 肝再生

Outline of Final Research Achievements

The impact of very early introduction of everolimus (EVR) on post liver transplant outcomes was investigated using a rat liver transplant model. Very early introduction of EVR and tacrolimus (TAC) after partial liver transplantation delayed liver regeneration, failed to suppress both rejection and infection, and decreased survival. Very early introduction of EVR and TAC after whole liver transplantation did not affect survival. If EVR is introduced immediately after living-donor liver transplantation, a larger graft size should be selected before transplantation, and careful EVR and TAC dosage adjustment after transplantation is necessary.

Free Research Field

移植外科

Academic Significance and Societal Importance of the Research Achievements

本結果により、実臨床において生体部分肝移植直後からエベロリムス（EVR）を導入する際に注意が必要であることが明らかとなった。同時に脳死全肝移植直後からのEVRの導入の臨床応用の可能性も明らかとなった。また、肝再生を抑制する薬物を投与した場合の部分肝移植後の転帰も示され今後の肝移植後の肝再生研究の参考となる。結果として肝移植後の免疫抑制戦略の発展に寄与するところが多い。